G Medical Innovations Ltd (ASX:GMV) is in trading halt pending an announcement regarding its Nasdaq listing.
The trading halt will remain in place until the beginning of trade on Monday August 26 or when an announcement is made to market – whichever occurs earliest.
The company established its UK headquarters last quarter and completed the pilot programs for its CE approved health monitoring solution, Patch.
The UK market for G Medical comprises the national healthcare system (NHS), private hospital groups, nursing and aged care facilities as well as other market participants.
UK’s healthcare system is compatible with G Medical’s business model and services and is an important territory for deployment, given both the Prizma and the Patch are regulatory approved for use within the UK.
G Medical Diagnostic Services Inc’s (GMEDx) Independent Testing Facility (IDTF) operations have seen consistent month on month new patient enrolment in the US.
As part of GMEDx’ growth strategy, the division will increase its sales force to provide for continued increase in patient enrolments within the market, as well as to push Prizma from POC to full commercialisation.